Treatment of hepatic cancer patients with a gluconeogenic diet: report of a case with hepatic metastases of malignant melanoma by Taketa, Kazuhisa et al.
Acta Medica Okayama
Volume 21, Issue 5 1967 Article 3
OCTOBER 1967
Treatment of hepatic cancer patients with a
gluconeogenic diet: report of a case with
hepatic metastases of malignant melanoma
Kazuhisa Taketa∗ Eiichi Miyata†
Kiyowo Kosaka‡
∗Okayama University,
†Okayama University,
‡Okayama University,
Copyright c©1999 OKAYAMA UNIVERSITY MEDICAL SCHOOL. All rights reserved.
Treatment of hepatic cancer patients with a
gluconeogenic diet: report of a case with
hepatic metastases of malignant melanoma∗
Kazuhisa Taketa, Eiichi Miyata, and Kiyowo Kosaka
Abstract
A case of malignant melanoma with metastases mainly to the liver and the right ilium was
treated with a gluconeogenic diet. The carbohydrate content of the diet was finally reduced to
5∼10 g per day and the remaining calories were derived from protein and fat. Increased blood
citrate and NEFA concentrations, increased ketone body formation and the maintenance of a rea-
sonable level of blood sugar confirmed the attainment of a gluconeogenic metabolic state. Definite
improvements in size of a hepatic tumor, serum alkaline phosphatase activity and the general con-
dition were observed transient1y during the dietary therapy. Growth of the tumor resumed despite
the continued gluconeogenic therapy, and the patient died of cardiac failure. Concentrations of
gluconeogenic enzymes, fructose-1, 6-diphosphatase, glutamic oxaloacetic transaminase and glu-
tamic pyruvic transaminase, were all found to be very low in the tumor tissue as expected.
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This study is an extension of a dietary therapy of a rat hepatoma1 to human
hepatomas and has been carried out in cooperation with Dr. POGELL and his
collaborators**. The principle of the therapy is to place the patient on a gluconeo-
genic diet and is based on their observation that a selective inhibition of the
growth in liver of the Novikoff hepatoma has been observed when rats are either
starved or placed on a gluconeogenic diet\ A minimum justification to extend
the experimental studies on animals directly to clinical materials is that the in-
operable hepatoma is still a fatal disease even with current chemotherapy and
also the possibility of placing a man on a gluconeogenic diet has been shown by
LIEB2•
The present report describes the first case of hepatic tumor treated with a
gluconeogenic diet. Although the patient was treated as a primary hepatoma,
the postmortem examination revealed hepatic metastases of malignant mela-
noma. In this study transient but definite subjective and objective improvements
have been obtained through the dietary therapy and the results of metabolic
studies on this case afford necessary information for future studies of the die-
tary therapy of primary hepatoma cases.
MATERIALS AND METHODS
Practical techniques of placing a hepatoma patient on a gluconeogenic diet
were essentially those suggested by GEORGE MANNs and those appeared in the
report by LIEB2• The carbohydrate content of the diet was gradually reduced
and the remaining calories were derived from protein and fat. No synthetic
diet was used in this study. The actual amounts of diet taken were checked for
every meal and the daily intakes of carbohydrate, protein, fat and total calory
* Attending physician.
** Department of Biochemistry, Albany Medical College, Albany, New York.
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were calculated by means of a food composition table4•
The effect of changing the dietary composition on general metabolic state
was followed by measurement of the metabolite levels in the blood and/or urine.
These included blood sugar5, urinary urea nitrogen and total ketone bodies'\
serum NEFA*7, citrate8, lactate9, pyruvate10 and a-ketoglutaratell• D-Ni-Graph
from Warner-Chilcott Laboratories was used for determination of urea nitrogen.
Other chemical tests were done by routine clinical laboratory methods. The
curative effect of the dietary regimen was checked by measurement of liver size
including tumor by palpation, the mid-abdominal circumference and serum
enzyme levels including alkaline phosphatasel~, glutamic oxaloacetic trans-
aminase13 and glutamic pyruvic transaminase13•
Enzymatic analyses of hepatic tumors were done on the autopsy specimens
obtained five hours after the death. To minimize the postmortem change in
liver or tumor enzymes, the liver was cooled by placing ice bags over the upper
abdomen immediately after death. Necropsied tissues were homogenized in 9
volumes of ice-cold, alkaline, isotonic potassium chloride solution14 per g of
tissue and centrifuged for 60 minutes at 30,000 xg at O°c. The supernatant
was used as enzyme sources. FDPase* and G6PDH* activities were determined
spectrophotometrically. FDPase assay was performed according to the method
described by TAKETA and POGELL15• The assay system for G6PDH contained
50 mM glycylglycine buffer (pH 7.5), 2.5 mM G6P*, 0.15 mM TPN+, 20 mM
MgCl2 and the supernatant. The system minus G6P served as a blank. The
spectrophotometric assays were conducted at 37°C with a Hitachi Model 139
spectrophotometer. Glutamic oxaloacetic and glutamic pyruvic transaminase
activities of the supernatant were determined colorimetrically13.
Fructose 1, 6-diphosphate, glucose G-phosphate and TPN+ were obtained as
the sodium salts from Sigma Chemical Company. Purified preparations of glu-
cose-6-phosphate dehydrogenase, phosphohexoisomerase, lactic dehydrogenase
and glutamic dehydrogenase were obtained from C. F. Boehringer & Soehne
GmbH.
OBSERVATIONS
Clinical History
K. KAW AWE, a 34 year old married sailor, was noted by a doctor to have
hepatic enlargement in July, 1966, when he had a high temperature of four
days' duration. He gradually lost weight in spite of his good appetite. He was
admitted to Okayama Rosai Hospital in November, 1966 for investigation of
* The abbreviations used are: NEFA, non-esterified fatty acids; FDPase, fructose-l,6-diphos-
phatase; D6PDI-I, glucose-6-phosphate dehydrogenase; and G6P, glucose 6-phosphate.
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low back pain, about which he had complained occasionally since he had blows
on both thighs in 1965. After admission he had an occasional fever and right
upper abdominal pains and was noted to have marked enlargement of the left
hepatic lobe. The presence of hepatic tumor was suspected by liver scanning
performed on February 1, 1667 (Fig. 1). A diagnosis of primary hepatoma*
was made by laparotomy and liver biopsy performed on February 3, 1967.
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Fig. 1 Filling defect on the liver scintillogram
The patient was transferred to Okayama University Hospital on February
28, 1967 for treatment of hepatoma with a gluconeogenic diet. At the time of
admission, he was emaciated and in apparent discomfort. He had a slight fever
in the afternoon and his appetite was slightly reduced. He complained of ex-
cessive perspiration at all times, general weakness and a continuous pain over
the right ilium.
His past medical history revealed an infection of the right eyeball in 1963
and loss of vision (right eye) since then. He had no particular dietary habits.
Physical Findings
Physical examination revealed blood pressure, 105/60 mm Hg; pulse, 86
and regular; temperature, 36.5°C; weight 42.5 Kg; and height 161 em. The
right eye had a scar formation and the pupil did not react to light and accom-
* The final diagnosis of hepatic metastases of malignant melanoma was established by postmor-
tem examination.
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modation. Conjunctivas were slightly anemic alld scleras not icteric. The heart
was slightly enlarged to the left. The lung-liver border was in the 5th inter-
costal space, and the excursion of the lung was slightly depressed. A slight
epigastric distention was noted. The liver was enlarged, firm and tender with
palpable nodules (Fig. 2). Swelling and tenderness over the right iliac crest
were noted (Fig. 2). The remainder of the physical findings were within nor-
mal limits.
NODULES
Fig. 2 Hepatic tumors and swelling of the right iliac crest at the time of admission to
Okayama University Hospital
Laboratory Findings
The hemoglobin concentration was 9.6 g per 100 ml; hematocrit value,
2996; erythrocytes, 3,390,000/mm\ with a reticulocyte count of 1.496; leu-
cocytes, 7,900/mm\ with 79 polymorphonuclear cells, 3 stab cells, 12 lympho-
cytes, and 6 monocytes per 100 cells; and platelets, 542,000/ mm3• There
was no hemorrhagic tendency. Sedimentation rate was 112 mm in one hour.
The results of urinalysis, stool examination, chest roentogenogram and electro-
cardiogram were normal. X-ray films of the right ilium disclosed an area of
abnormal bone architecture suggestive of a tumor metastasis. The serum biliru-
bin, cholesterol, uric acid, creatine, creatinine, Na, Cl, Ca, and K were all
normal. The urinary excretion of creatine was 120 mg a day. The Millon
reaction of urine was positive in most of occasions. The result of the oral glu-
cose tolerance test was slightly diabetic. Fasting levels of blood citrate was 0.22
mM; a-ketoglutarate, 0.021 mM, lactate, 1.2 mM; pyruvate, 0.089 mM; and
NEFA, 0.64 mM. The citrate level dropped to 0.056 mM in 60 minutes follow-
ing 30 g oral glucose administration. Non-specific serum-protein flocculation
tests were normal except for the cobaltous chloride reaction of R/6• The total
serum protein was 6.8 g per 100 ml, with 3196 albumin, 796 aI-globulin, 17%
a2-globulin, 1696 11-globulin and 2996 r-globulin. The serum alkaline phospha-
tase was 16.6 Bessey units; lactic dehydrogenase, 2,100 Wroblewsky units;
cholinesterase, 0.85.d pH; and glutamic oxaloacetic transaminase and glutamic
pyruvic transaminase, 56 and 36 Karmen units, respectively.
4
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Clinical Summaries
The patient was placed on a regular hospital diet during the period of con-
trol examination. Thereafter, the carbohydrate content of the diet was gradually
lowered and the amount of protein and fat increased; his daily intake of total
calory being slightly increased. The daily carbohydrate content was finally
reduced to 5.......,10 g, which was inherent as a result of the intake of glycogen-
containing meat. The conclusive gluconeogenic diet chiefly consisted of beef,
pork, ham, cheese, eggs, fish, mayonnaise, gelatin, and less than 40 g per day
of tomato, cucumber or lettuce. Artificial flavor and sweetening agent (sodium
cyclamate) were also used. The dietary regimen used for the therapy is sum-
merized in Fig. 3. Drip infusion of Ringer solution with 10 mg of vitamin B2,
10 mg pyridoxal phosphate, 500 mg of vitamin C and 20 mg of vitamin K1 and
oral administration of daily doses of 1 to 2 g Vitaplex* with additional 6 mg
vitmin B2, 30 to 60 mg pyridoxal phosphate, 30 mg vitamin~, 30 mg nicotin-
amide, 200 mg calcium pantothenate and 50 mg a-tocopherol were continued
throughout the therapy. Two g of calcium lactate and 6 to 9 tablets of Eizym*,
a digestive enzyme preparation, were also used.
The patient lost 3 kg in weight in one week after hospitalization, and no
further loss in weight was seen thereafter. After the carbohydrate content of
the diet was reduced to 100 g per day, he complained of hunger feeling and
thirsty, and complete satiety did not result after eating. By increasing the
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Fig. 3 Daily intake of carbohydrate, fat, protein and total calory during the entire course
of the dietotherapy
* Eisai Pharmaceutical Co.
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amount of fat and protein in the diet, the hyperhydrosis and general weakness
were partially removed and his appetite increased. The patient could well tole-
rate a considerably large amount of fat. His general condition was even slightly
improved from 12 to 20th hospital days. The swelling observed on the anterior
part of the right ilium also became less marked in this period, but the pain
persisted. A frequent block of right femoral and sciatic nerves with xylocaine
was effective in relieving the pain.
A positive test for urinary acetone bodies was always obtained after the
daily carbohydrate intake was reduced below 40 g. The result of quantitative
estimation of urinary total ketone bodies is given in Fig. 4 together with the
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Fig. 4 Blood sugar levels and urinary excretions of urea and total ketone bodies during
the therapy with the gluconeogenic diet
0-0, blood sugar; .-., urinary urea-N; and 6----6, urinary total ketone bodies.
results on the urinary secretion of urea and the blood sugar. Further reduction
of carbohydrate content as low as 5......, 10 g per day did not result in an increased
ketone body secretion. The fasting blood sugar levels were relatively low but
well maintained around 60 mg per 100 ml throughout the period of gluconeoge-
nic diet except for the last two days before his death, when he developed hypo-
glycemia. Postprandial rises in the blood sugar with gluconeogenic diets were
minor as compared with the rises after oral administration of larger amounts of
glucose (Fig. 5).
The levels of citrate and NEFA in the blood increased markedly after the
carbohydrate content in the diet was reduced to 40 g per day. The citrate in-
creased further but transiently after reduction of the carbohydrate content to 5
6
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Fig. 5 Blood sugar levels after oral glucose administrations in the control period compared
with those after meals during the dietotherapy
--10 g per day. The blood pyruvate, lactate and a-ketoglutarate levels were
slightly lower when the citrate and NEFA concentrations were high. The course
of these metabolite changes in the blood is summerized in Fig. 6. The size of
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Fig. 6 Effects of the gluconeogenic diet on metabolite concentrations in the blood
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the right lobe of liver and the alkaline phosphatase activity of serum decreased
slightly when the citrate level was high and an improvement in his general con-
ditions was noted (Figs. 7 and 8). The left lobe of liver did not change in size.
After about three weeks of hospitalization, the patient began to complain
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Fig. 7 Changes in liver size and mid-abdominal circumference during the therapy with
the gluconeogenic diet
Liver sizes below the costal margin: .-., on the right mammillary line; 0--0, on the
left mammillary line. --, Mid-abdominal circumference.
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Fig. 8 Serum enzyme activities during the therapy with the gluconeogenic diet
ALPase, alkaline phosphatase; GOT, glutamic oxaloacetic transaminase; and GPT, glutamic
pyruvic transaminase
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of intractable general weakness, and tachypnea and tachycardia were noted.
The result of the heart examination by electrocardiogram and phonocardiogram
revealed Hegglin's syndrome, suggesting the presence of myocardial damage
related to metabolic disturbancesl7• Intravenous administration of 1 g potassium
aspartate, 1 g magnesium aspartate, 20 mg adenosine triphosphate, 30 mg thia-
mine pyrophosphate, 25 mg a-lipoic acid and 20 mg flavin adenine dinucleotide
in the Ringer solution was instituted in an attempt to correct the myocardial
damage.
At this time the presence of a metabolic acidosis was evident from the in-
creased blood citrate and urinary ketone bodies, but the total carbon dioxide
content in the blood was not reduced. Since the acidosis was not progressive,
the daily carbohydrate content was further reduced to 5 --10 g and the total
ealory increased by giving more fat. With the conclusive gluconeogenic diet,
the general weakness, hunger feeling, tachypnea and tachycardia did not seem
to increase further.
Around the 30th hospital day, an increasing distension in the epigastrium
was noted and a new solid tumor became palpable. An increase in size of the
right liver lobe was also noted and the blood enzyme activities markedly in-
creased again (Figs. 7 and 8). He complained of sense of fullness in the epigast-
rium and his appetite reduced. The blood citrate tended to decline and the
NEFA returned normal (Fig. 6). By this time, most of the subcutaneous adi-
pose tissue seemed exhausted.
On the 35th day he developed hypoglycemia, which necessitated a frequent
intravenous infusion of glucose solution and administration of ACTH. Although
the hypoglycemia could be corrected by the parenteral glucose administration,
the pulse pressure became small and the patient died of cardiac failure on 36th
day.
Postmortem Examination
The main pathological diagnosis was a widely disseminated malignant
melanoma. No melanomatous tumor was detectable on the skin and the
primary lesion could not be disclosed. The autopsy findings revealed a large
metastatic tumor formation at the right hip joint and a compression of the right
femoral artery, vein and nerve. Metastases t) the following organs were also
found: lung (bilateral), liver, kidney (bilateral), right adrenal, pancreas, serosa
of the rectum, bone marrow of thoracic vertebrae, and several lymph nodes.
The liver was markedly enlarged (4,600 g) due to massive metastasis of
melanoma, leaving apparently intact liver tissue as small as ten per cent of the
total. The left lobe was almost replaced by a solid melanotic tumor mass. The
tumor mass in the right liver lobe was partly amelanotic (Fig. 9). Microscopi-
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cally the tumor cells varied largely in cell type and showed pleomorphism and
pronounced atypia with varing amounts of melanin pigment (Fig. 10). The
staining characteristics of the pigmented materiaP8 and the darkening of a less
pigmented tumor mass upon exposure to the air substantiate that the pigment
is melanin rather than bile or iron.
A generalized atrophy of adipose tissue was marked and the tissue was
microscopically similar to that of a new born baby. Pathological findings of the
cardiovascular system were dilatations of the right atrium and left ventricle and
slight atrophy and fibrosis of myocardium. The cause of death is subacute
cardiac failure.
The activities of hepatic tumor fructose-I, 6-diphosphatase, glucose-6-phos-
phate dehydrogenase, glutamic oxaloacetic transaminase and glutamic pyruvic
transaminase measured with the autopsy material are given in Table 1. Activi-
Table 1 Enzyme activities in hepatic tumor tissues
Enzyme
i FDPase I GOT I GPT I G6PDH
Ii m,umoles/min. /mg Karmen U. /mg I Karmen U. /mg I m,umoles/min. /mg
I protein protein protein i protein
I II83 1050
Intact liver
(right lobe)
Amelanotic tumor
(right lobe)
Melanotic tumor
(right lobe)
Melanotic tumor
(left lobe)
38
46
2.6
670
750
28
450
190
220
10
15
31
40
40
Abbreviations used for enzymes: see the legend to Fig. 8 and the foot-note in the text.
ties of the three gluconeogenic enzymes were all very low in a melanotic tumor
tissue of the left lobe, which showed no appreciable change in size during the
dietotherapy, and slightly reduced in both melanotic and amelanotic tumors of
the right lobe, which grew rapidly at the end of the dietotherapy. A microsco-
pical examination of the counterpart of the tissues used for enzyme assay dis-
closed that the tumor tissue from the left lobe was not contaminated with
liver parenchymal cells but the rapidly growing right-lobe tumor tissues, with
or without melanin, retained some intact liver parenchymal cells. The activities
of glucose-6-phosphate dehydrogenase were rather high in the tumor tissues.
COMMENTS
Since in the original report of HUBBARD and POGELL the curative effect of
carbohydrate deprivation on the growth of Novikoff hepatoma has been shown
to be limited to the hepatic tumor\ the most pertinent subject to be tested in
10
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Fig. 9 Cross-sections of the liver. indicating intermingled melanotic and amelanotic tumor
masses. R, right liver lobe; L, left liver lobe.
Fig. 10 Microscopic findings of tumor tissues showing pleomorphism and atypia of mela-
noma cells.
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extension of the rat hepatoma studies to clinical materials is naturally a primary
hepatoma. The present case treated as a primary hepatoma was unfortunately
proved to be malignant melanoma, which is notorious for its malignancy, and
its metastases to the liver. A case with a similar difficulty in diagnosis has been
reported where an apparent metastatic melanoma to the liver behaved clinically
and histologically as a hepatocarcinoma19• Even with these unfavorable situations,
considerable improvements in general conditions, hepatic tumor size and serum
alkaline phosphatase activity were seen transiently during the gluconeogenic
dietary therapy. Causes of the exacerbation observed in the latter stage with
the even more strict gluconeogenic diet are not known. It is hard to speculate
that the tumor cells became resistant to the unfavorable metabolic conditions
caused by carbohydrate deprivation. A spontaneous cessation of tumor growth
might be seen transiently in the natural course of tumor development. How-
ever, in the present case the growth of the right hepatic tumor and the increase
in the serum alkaline phosphatase activity had been so rapid until the gluconeo-
genic diet was instituted that it leaves little possibility for the spontaneous arrest
of the tumor growth.
Although no idea of biochemical mechanism of the inhibition of tumor
growth by carbohydrate deprivation is available at present, one possible expla-
nation has been suggested by HUBBARD and POGELL\ namely, the inhibition of
phosphofructokinase, and hence the active glycolysis of tumor cells by citrate.
The concentration of this metabolite is known to increase under gluconeogenic
conditions20• Increased free fatty acids in the fasting blood are also known to
suppress glucose utilization2\ The inhibition of active tumor glycolysis by cit-
rate and free fatty acids would curtail the utilization by tumor of glucose which
is produced by intact liver cells as a result of gluconeogenesis and would block
the unfavorable metabolic interaction between normal and tumor cells. This is
an attractive idea in view of the fact that the tumor growth of the right hepatic
lobe ceased when the citrate and NEFA levels in the blood were high, and the
tumor resumed to grow rapidly when the citrate tended to decline and the
NEFA returned normal. From the fact that the patient developed hypoglyce-
mia in the latter stage, it is evident that the utilization of glucose by the tumor
or peripheral tissues was markedly enhanced at the lower citrate and NEFA
concentrations. The complete exhaustion of peripheral adipose tissue and the
development of hypoglycemia despite the intake of tremendously large amounts
of fat suggest that in carbohydrate deprivation the requirement of fat for the
tumor-bearing subject is much greater than that for a healthy man2•
Insufficient production of glucose by the intact liver is also very probable,
because the amount of apparently intact surviving liver tissue was as small as
ten per cent of the total hepatic tumor mass. The presence of an impaired utili-
12
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zation of fatty acid by the liver is not evident, because a considerable amount of
ketone bodies were produced throughout the dietotherapy, and no fat accumula-
tion in the liver was found in necropsy.
The ketone body formation is thought to be an index of enhanced glueo-
neogenesis22, and it may not be harmful as far as it does not cause a severe meta-
bolic acidosis, because the peripheral tissues can utilize ketone bodies as an energy
source. In fact, the ketone body concentration in the blood or the amount ex-
creted in the urine in the present case did not increase with the increasing intake
of dietary fat. This could be interpreted as a result of adaptive mechanism of
ketone body-utilizing tissue metabolism rather than a limited production of
ketone bodies. On the other hand, the incomplete breakdown of fatty acid to
acetoacetate would reduce the caloric efficiency of fat oxidation in the liver, and
extra energy required for the increased gluconeogenesis must be supplied by
ATP formation in 11-oxidation of fatty acids. This would explain the necessity
of giving extraordinary large amounts of fat in gluconeogenic diet, and actually
the patient could take fat as high as 200 g per day. It is not known, however,
whether the predominant utilization of fatty acids in the heart muscle is associat-
ed with the myocardial damage, which was the direct cause of death in the
present case.
SUMMARY
A case of malignant melanoma with metastases mainly to the liver and the
right ilium was treated with a gluconeogenic diet. The carbohydrate content of
the diet was finally reduced to 5--10 g per day and the remaining calories were
derived from protein and fat.
Increased blood citrate and NEFA concentrations, increased ketone body
formation and the maintenance of a reasonable level of blood sugar confirmed
the attainment of a gluconeogenic metabolic state. Definite improvements in
size of a hepatic tumor, serum alkaline phosphatase activity and the general con-
dition were observed transient1y during the dietary therapy. Growth of the
tumor resumed despite the continued gluconeogenic therapy, and the patient
died of cardiac failure.
Concentrations of gluconeogenic enzymes, fructose-I, 6-diphosphatase, glu-
tamic oxaloacetic transaminase and glutamic pyruvic transaminase, were all
found to be very low in the tumor tissue as expected.
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